Skip to main content
Delfa

← All trials/NCT07301437

Not yet recruitingPhase 4

RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

0

Recruiting sites

-

Estimated enrollment

120

Study population

Obesity / overweight

Eligibility highlights

•BMI ≤35

Primary endpoint

•Weight loss

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07301437
Org study IDKY-2025-202

Timeline

Milestones

Study first posted2025-12-24actual
Last update posted2026-03-23actual
Study start2026-05-01estimated
Primary completion2027-08-31estimated
Study completion2027-08-31estimated

Assets

Investigational agents

Liraglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)
•Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.
•No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.

Exclusion criteria

•Allergy to liraglutide, orlistat or excipients
•Severe liver and kidney dysfunction: ALT or AST> three times the upper limit of normal, or eGFR <30 mL/min
•Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism
•Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers
•Pregnant or lactating women
•Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint
Primary/protocol endpoint/low confidence

weight loss

Time frame:6 months

descriptive, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.